Is Jazz Pharmaceuticals (JAZZ) One of the Best Cheap Biotech Stocks to Buy Now?
Jazz Pharmaceuticals (NASDAQ:JAZZ) is one of the best cheap biotech stocks to buy now.
Jazz Pharmaceuticals Plc (JAZZ)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | EcoR1 Capital Oleg Nodelman | 1,706,469 | $290,099,730 | 13.16% | |
| 2. | Millennium Management Israel Englander | 1,202,711 | $204,460,870 | +347% | 0.09% |
| 3. | AQR Capital Management Cliff Asness | 877,267 | $149,135,332 | +26% | 0.08% |
| 4. | Renaissance Technologies Jim Simons | 836,774 | $142,251,580 | -10% | 0.22% |
| 5. | GMT Capital Thomas E. Claugus | 638,500 | $108,545,000 | -20% | 5.66% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $103.00 | 1,621 | $166,961.54 | 101,621 | 2025-05-12 | Filing | |
| $99.71 | 100 | $9,971.00 | 100,000 | 2025-05-09 | Filing | |
| $98.91 | 19,216 | $1,900,677.62 | 99,900 | 2025-05-09 | Filing | |
| $98.10 | 80,684 | $7,915,471.55 | 80,684 | 2025-05-09 | Filing | |
| $119.65 | 12,000 | $1,435,800.00 | 27,932 | 2024-03-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $192.00 | 3,415 | $655,680.00 | 7,024 | 2026-02-27 | Filing | |
| $190.91 | 1,117 | $213,243.45 | 9,235 | 2026-02-27 | Filing | |
| $194.11 | 1,253 | $243,222.21 | 10,352 | 2026-02-26 | Filing | |
| $193.60 | 197 | $38,138.85 | 58,818 | 2026-02-26 | Filing | |
| $192.79 | 1,009 | $194,526.62 | 59,015 | 2026-02-26 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,917,142 | $1,005,914,140 | 0.01% | |
| 2. | 5,451,241 | $926,710,907 | 0.02% | |
| 3. | 2,666,602 | $453,322,340 | 0.06% | |
| 4. | 2,623,303 | $445,964,615 | 0.09% | |
| 5. | 1,837,793 | $312,424,810 | 0.01% |
News See All
12 Cheap Biotech Stocks to Buy Now
On February 27, Eli Casdin, Casdin Capital CEO, appeared on CNBC’s ‘Closing Bell’ to talk about the biotech sector.
11 Best Pot Stocks to Buy According to Hedge Funds
The global cannabis industry is undergoing a structural transformation as legalization expands for both medical and adult use across multiple regions.
Jazz Pharmaceuticals plc (JAZZ) Jumps Nearly 30% on Strong Q3 and Cancer Drug Trial Progress
The Harbor Capital Advisors released its “Mid Cap Value Fund’s” Q4 2025 investor letter. A copy of the letter can be downloaded here.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q4 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Jazz Pharmaceuticals Fourth Quarter 2025 Earnings Conference Call.
Truist Securities Raises Jazz Pharmaceuticals (JAZZ) Price Target After HERIZON-GEA Trial
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the mid-cap stocks to buy according to top investors.
Top Investors' Stock Portfolio: 10 Mid-cap Stocks To Buy
The Fed's change from higher interest rates to rate cuts has caused what Amy Y. Zhang, portfolio manager of the Alger Mid Cap 40 ETF, refers to as a "headwind to tailwind" shift in mid-cap companies.
Jazz Pharma (JAZZ) Hits Fresh 52-Week High on Strong Cancer Treatment Trial
In a statement, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) said that it recorded positive results for its phase 3 clinical trial for Ziihera, in combination with chemotherapy, with or without the PD-1 inhibitor...
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q3 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Jazz Pharmaceuticals 2025 Third Quarter Earnings Conference Call.
Jazz Pharmaceuticals (JAZZ) Gets Price Target Boost Following Positive Xywav Phase 4 Data
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the stocks with low beta that can beat market volatility.
Hedge Fund Resource Center